<DOC>
	<DOC>NCT02845804</DOC>
	<brief_summary>The objectives of this study are 1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent 2. To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition™/Alpine™ stent 3. To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition™/Alpine ™ stent and other contemporary drug-eluting stents which had established their own registry</brief_summary>
	<brief_title>Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis</brief_title>
	<detailed_description>Secondary endpoints of this study are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI Target vessl failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, and any repeat revascularization Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient agrees to participate in this study by signing the informed consent form. Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form There are no exclusion criteria for this registry.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>everolimus-eluting stents</keyword>
</DOC>